BFLY — Butterfly Network, Inc.

Butterfly Network Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $21.5 million, up 5% year-over-year, driven by higher average selling prices and increased volume, particularly in the U.S.
• U.S. Revenue: $16.1 million, slightly up from the prior year, attributed to e-commerce sales and veterinary distribution.
• International Revenue: $5.4 million, a 4% increase, primarily due to the international launch of the iQ3.
• Product Revenue: $14.6 million, an 8% increase year-over-year.
• Software and Services Revenue: $6.9 million, flat compared to the prior year.
• Gross Margin: Adjusted gross margin improved to 63.9% from 60% despite a noncash inventory write-off of $17.4 million, resulting in a negative gross margin of -17.5%.
• Adjusted EBITDA Loss: $8.1 million, an improvement from a loss of $8.4 million in Q3 2024.
• Cash Position: $148 million in cash and cash equivalents, with a trailing 12-month cash burn of $31.5 million.

2. Strategic Updates and Business Highlights

• Product Strategy: Continued focus on expanding the point-of-care ultrasound (POCUS) market with the iQ3 and upcoming P5.1 chip, which is expected to enhance imaging capabilities significantly.
• AI Integration: Successful implementation of AI tools, including the auto beeline counter, which demonstrated improved patient management and cost savings in a recent study.
• Education Initiatives: Launched Butterfly Garden, an ecosystem for AI tools aimed at increasing ultrasound adoption among healthcare professionals.
• Partnerships: Development of the HeartFocus app, which aids in echocardiograms, and ongoing collaborations with the Gates Foundation for AI-powered gestational age calculators in low-resource settings.

3. Forward Guidance and Outlook

• Full Year Revenue Guidance: Reaffirmed at $91 million to $95 million, with Q4 expected to contribute $25 million to $29 million.
• Adjusted EBITDA Loss Guidance: Tightened to a range of $32 million to $35 million for the full year, with Q4 expected to be between $9 million and $12 million.
• Sales Pipeline: Anticipated improvement in sales momentum in 2026, with several large deals still in the pipeline.

4. Bad News, Challenges, or Points of Concern

• Government Shutdown: Ongoing federal government shutdown could potentially delay deal timing and impact customer cash flow, although currently not seen as a significant risk.
• Purchase Delays: Some customers are delaying purchase decisions due to macroeconomic factors, affecting U.S. hospital and enterprise channels.
• Subscription Revenue: Lower renewal rates for individual subscriptions noted, with churn impacting overall software revenue.
• Inventory Write-Off: Noncash charge for excess inventory of previous generation chips, reflecting a shift in demand towards the iQ3.

5. Notable Q&A Insights

• Sales Pipeline Confidence: Management expressed confidence in the pipeline, noting that while deals are being delayed, they are not being lost. Anticipated larger deals range from 100 to 200 probes.
• Impact of AI Studies: The economic benefits demonstrated in studies, such as the one from Robert Wood Johnson, are expected to strengthen sales arguments and drive interest in 2026.
• Home Care Program: Management remains optimistic about the home care pilot program, emphasizing that the timing of finalization is beyond their control.
• P5.1 Chip Development: Management is confident in the upcoming P5.1 chip launch, which is expected to significantly enhance product offerings and market competitiveness.

Overall, Butterfly Network reported steady growth amid challenges, with a strong focus on innovation and strategic partnerships as it navigates a complex market landscape.